Background: A better understanding of the relative risks and benefits of common treatment options for abnormal uterine bleeding (AUB) can help providers and patients to make balanced, evidence-based decisions.
Objectives: To provide comparative estimates of clinical outcomes after placement of levonorgestrel-releasing intrauterine system (LNG-IUS), ablation, or hysterectomy for AUB.
Search Strategy: A PubMED search was done using combinations of search terms related to abnormal uterine bleeding, LNG-IUS, hysterectomy, endometrial ablation, cost-benefit analysis, cost-effectiveness, and quality-adjusted life years.
Selection Criteria: Full articles published in 2006-2016 available in English comparing at least two treatment modalities of interest among women of reproductive age with AUB were included.
Data Collection And Analysis: A decision tree was generated to compare clinical outcomes in a hypothetical cohort of 100 000 premenopausal women with nonmalignant AUB. We evaluated complications, mortality, and treatment outcomes over a 5-year period, calculated cumulative quality-adjusted life years (QALYs), and conducted probabilistic sensitivity analysis.
Main Results: Levonorgestrel-releasing intrauterine system had the highest number of QALYs (406 920), followed by hysterectomy (403 466), non-resectoscopic ablation (399 244), and resectoscopic ablation (395 827). Ablation had more treatment failures and complications than LNG-IUS and hysterectomy. Findings were robust in probabilistic sensitivity analysis.
Conclusions: Levonorgestrel-releasing intrauterine system and hysterectomy outperformed endometrial ablation for treatment of AUB.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ijgo.12293 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pain scores at the insertion of the levonorgestrel-releasing intrauterine system among paralympic athletes: Findings from Kyleena® Paralympic sport performance study.
Eur J Obstet Gynecol Reprod Biol
December 2024
Universidade Estadual de Campinas (UNICAMP), Brazil.
Reversal of Endometriosis-Induced Unilateral Ureteral Obstruction and Hydronephrosis With Medical Therapy.
Cureus
November 2024
Obstetrics and Gynecology, Hung Vuong Hospital, Ho Chi Minh, VNM.
Endometriosis is a common condition among women of reproductive age worldwide, with the urinary tract being the second most frequently affected extragenital organ system, particularly the bladder and ureters. Ureteral endometriosis (UE) is relatively rare, often asymptomatic, and can lead to progressive renal function loss if not addressed promptly. Early diagnosis and intervention are essential, requiring a high index of suspicion.
View Article and Find Full Text PDFCost-effectiveness of long-acting progestogens versus the combined oral contraceptives pill for preventing recurrence of endometriosis-related pain following surgery: an economic evaluation alongside the PRE-EMPT trial.
BMJ Open
December 2024
Health Economics Unit, Department of Applied Health Science, College of Medicine and Health, University of Birmingham, Birmingham, B15 2TT, UK
Objectives: To evaluate the cost-effectiveness of long-acting progestogens (LAP), including levonorgestrel-releasing intrauterine system (LNG-IUS) and depot-medroxyprogesterone acetate (DMPA), compared with the combined oral contraceptives pill (COCP) in preventing recurrence of endometriosis-related pain postsurgery.
Design: Within-trial economic evaluation alongside a multicentre, pragmatic, parallel-group, open-label, randomised controlled trial (Preventing Recurrence of Endometriosis by means of Long-Acting Progestogen Therapy trial).
Setting: Thirty-four UK hospitals recruiting participants from November 2015 to March 2019.
Tips and tricks for the management of contraceptive etonogestrel implant in clinical practice: an Expert Opinion.
Eur J Contracept Reprod Health Care
December 2024
Department of Medical and Surgical Sciences for Mother, Child and Adult, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
Article Synopsis
- The global use of long-acting reversible contraceptives (LARCs) is rising because they more effectively prevent unintended pregnancies compared to short-acting methods, especially in teens.
- LARCs include options like intrauterine devices and subcutaneous implants, with specialized training required for their application.
- This Expert Opinion focuses on the etonogestrel (ENG)-releasing implant, offering updated guidance on insertion, removal, and managing unscheduled bleeding based on extensive clinical experience.
Contraception with levonorgestrel-releasing intrauterine system versus copper intrauterine device: a meta-analysis of randomized controlled trials.
EClinicalMedicine
December 2024
Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Background: Globally, approximately 19.4% of women of reproductive age use intrauterine contraception, encompassing both copper intrauterine devices (Cu-IUDs) and levonorgestrel intrauterine devices (LNG-IUDs). Despite current guidelines endorsing intrauterine contraception as a primary method, there remains debate regarding device selection.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!